Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation
about
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Alternative donor transplant of benign primary hematologic disordersPost-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantationDesensitization for solid organ and hematopoietic stem cell transplantationGenetic barriers in transplantation medicineHaploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectivesHarnessing adaptive natural killer cells in cancer immunotherapySuccessful "in-flight" activation of natural killer cells during long-distance shippingDonor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies.Haploidentical transplantation: the search for the best donor.Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignanciesDonor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease.Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.The outcomes of family haploidentical hematopoietic stem cell transplantation in hematologic malignancies are not associated with patient age.Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamideNonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamidePresent and Future of Allogeneic Natural Killer Cell TherapyHLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.KIR Genes and Patterns Given by the A Priori Algorithm: Immunity for Haematological Malignancies.Genetics of graft-versus-host disease: the major histocompatibility complex.Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid LeukemiaStrategies in haploidentical stem cell transplantation in adults.Overview of the progress on haploidentical hematopoietic transplantation.Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.Natural killer cell education and tolerance.The great debate: haploidentical or cord blood transplant.Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Use of NK cell activity in cure by transplant.New strategies for haploidentical transplantation.Immunotherapeutic approaches to treat multiple myelomaHuman NK cells: from surface receptors to the therapy of leukemias and solid tumorsExperts' considerations on HLA-haploidentical stem cell transplantation.T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation.Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia.
P2860
Q26748867-A1503C5A-B76A-4AEB-84F3-F3B2C43A6E1BQ26823398-3BEFB979-01D5-4F75-8DF1-E9105F82550CQ26852474-4A3585B5-8F8C-435A-BA2F-DBCE05D8E59FQ26863564-29F38357-CAA7-4CF4-8E2D-84AB84C03685Q28069956-DB5A77B6-DFD5-44C6-AB2D-46636BAE3481Q28080452-EA084625-22EE-403A-88F2-EEF66C7C4376Q28081448-64394B71-9B91-4747-A963-549629BB9411Q33787299-34860BC8-F2B6-4968-A76B-43495775C377Q33856960-62FE8079-AF66-4FD2-998D-DFE3D7C23501Q34019548-2F12495C-74E4-417E-BF1E-DDF579AF03B6Q34088081-B2EDB850-7CEB-451C-B515-A0F57688AC3FQ34175568-B0D40A96-7422-4808-BFE0-E2763C43CD6CQ34193507-EFF6D705-32C5-46C0-A90C-9AEDBA2C4E30Q34615804-20245F2E-8F9A-492C-B79F-E60811840D83Q35029441-1605E5D1-1AF1-4F48-A03B-E022C9500BA0Q35041195-C3041551-A54A-4CE1-8811-ED822248FFA8Q35083562-57F074C6-C816-40D5-B868-1111F9F560ADQ35478934-14591A50-8AF5-489A-A53A-5D4A67045F43Q35505839-EB3D0DFE-42AD-4188-B704-A17123CB2A0DQ35677351-D4485E13-F261-42CF-976E-561EECE22019Q35678422-BD826792-FF74-4A3D-9522-8D821E19A101Q36163789-2B64F108-B020-4702-90E6-1A2D51D82867Q36766250-CA8EFA5A-5807-4E02-88F3-16CCEB583F61Q37024340-201E4147-4C58-49AE-AC77-8FB1D09B359BQ37418956-E9823ECD-0749-4A85-9ABF-FAA1D0A89F18Q37522577-B7BAC242-1312-44C9-935A-1ADFEC5DF248Q37590606-D4BE5A22-7B38-4990-8E53-3E286FF4AF4BQ37789866-D424B493-1BD9-4C10-852B-A976AD54FFD5Q37806066-3E4360C2-4A27-4BF8-83F3-F6976E61DDFEQ37844655-A06917DE-91DF-4BB9-A8D1-C032D4190A7CQ37905034-05A2E9AD-4FFC-4D25-A757-637B2A2265EFQ37910960-AE925730-15D2-49FD-9A13-52FB18CC1021Q37978777-ADEC1BB2-7472-40EF-8CF8-8FD7AD27505CQ38171067-C9A09DB4-0249-4E00-A544-14196E96DA01Q38196803-BD9E7655-5E62-4FAB-BB66-1B07B8ED83F5Q38198728-CB79AFE7-2834-4321-BA49-57A2ED5C5E66Q38212957-A09E304B-469E-4597-870C-5599D6AD1890Q38569646-965F7A06-62C2-4859-ADEA-225493947187Q38656322-DE1CEFB7-5FA2-4643-8700-911A2224B5BEQ38870274-18040862-86C0-46BF-AA3B-8AA56EDADD82
P2860
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Improved survival with inhibit ...... al bone marrow transplantation
@ast
Improved survival with inhibit ...... al bone marrow transplantation
@en
type
label
Improved survival with inhibit ...... al bone marrow transplantation
@ast
Improved survival with inhibit ...... al bone marrow transplantation
@en
prefLabel
Improved survival with inhibit ...... al bone marrow transplantation
@ast
Improved survival with inhibit ...... al bone marrow transplantation
@en
P2093
P2860
P1476
Improved survival with inhibit ...... al bone marrow transplantation
@en
P2093
Ephraim J Fuchs
Heather J Symons
M Sue Leffell
Marianna Zahurak
Nancy D Rossiter
Richard J Jones
P2860
P304
P356
10.1016/J.BBMT.2009.11.022
P577
2009-12-02T00:00:00Z